Novavax (NVAX) Assets Average (2011 - 2026)
Novavax (NVAX) posted quarterly Assets Average of $1.1 billion for Q1 2026, down 22.21% year-over-year from $1.4 billion in Q1 2025, and down 5.8% quarter-over-quarter from $1.2 billion in Q4 2025.
Novavax (NVAX) Assets Average (2011 - 2026) Analysis & Trends
Novavax's Assets Average history runs 16 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Assets Average fell 22.21% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (down 22.21% YoY), while the FY2025 annual figure was $1.4 billion, down 18.49% from the prior year.
- Assets Average for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
- The five-year high for Assets Average was $2.7 billion in Q2 2022, with the low at $1.1 billion in Q1 2026.
- The 5-year median for Assets Average is $1.6 billion (2024), against an average of $1.8 billion.
- The sharpest annual moves came in 2022 and 2023: Assets Average increased 29.13% in 2022, then sank 40.86% in 2023.
- Novavax's Assets Average stood at $2.3 billion in 2022, then declined by 23.67% to $1.7 billion in 2023, then declined by 5.26% to $1.6 billion in 2024, then dropped by 28.0% to $1.2 billion in 2025, then slipped by 5.8% to $1.1 billion in 2026.
- Business Quant data shows NVAX's Assets Average at $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 999.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 999.37 Mn |
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 1.18 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 1.43 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.77 Bn |
| Jun 30, 2024 | 1.59 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.73 Bn |
| Sep 30, 2023 | 1.67 Bn |
| Jun 30, 2023 | 1.61 Bn |
| Mar 31, 2023 | 1.90 Bn |
| Dec 31, 2022 | 2.26 Bn |
| Sep 30, 2022 | 2.45 Bn |
| Jun 30, 2022 | 2.73 Bn |
| Mar 31, 2022 | 2.71 Bn |
| Dec 31, 2021 | 2.57 Bn |
| Sep 30, 2021 | 2.66 Bn |